Comment from Consumer Healthcare Products Association (CHPA)

Summary: The Consumer Healthcare Products Association (CHPA), a trade association representing manufacturers of over-the-counter medicines and supplements, supports the FDA's draft guidance on using AI in regulatory decision-making. They advocate for additional clarity on risk-based frameworks, transparency for third-party models, lifecycle management for AI models, and specific guidance on using real-world data and post-market surveillance.